Dermatology

There are many herbal therapies available for dermatological diseases that patients have already begun to discover. Dermatologists must be educated not only in the benefits of these therapies, but must also be aware of some of the risks and adverse effects.

This article reviews the use of intravenous immunoglobulin (IVIG) in dermatology, highlighting its role in treating autoimmune and inflammatory skin diseases. It discusses how IVIG reduces the need for steroids or immunosuppressants and its applications in conditions such as autoimmune bullous dermatoses, dermatomyositis, and Stevens-Johnson syndrome. The article also addresses dosing regimens, potential adverse effects, and the importance of ongoing research to further understand the efficacy and safety of IVIG in dermatologic treatments.

Solid organ transplant recipients have an increased incidence of skin cancer, resulting in significant morbidity and mortality post-transplantation. This article studies systemic retinoids, and other chemopreventative agents for high risk patients.

Allergic contact dermatitis (ACD) may account for at least 20% of all childhood dermatitis. Clinically, its morphology is identical to other forms of dermatitis in acute, subacute and chronic forms. A persistent or unusual and localized pattern is often the key to diagnosis.

Update on Quadrivalent Human Papillomavirus Recombinant Vaccine GARDASIL®, Infliximab Remicade®, Humira® Penq, and news about Malignant Melanoma and Scleroderma research.

Imiquimod 5% cream (Aldara™, Graceway Pharmaceuticals) is an immune response modifier used for the topical treatment of anogenital warts in non-HIV-infected patients. Several randomized controlled trials have demonstrated that imiquimod 5% cream is a safe and efficacious treatment.

Topical therapy forms the cornerstone of treatment in the management of psoriasis. Topical options, vehicle advances, and treatment efficacy of several topicals are discussed for managing psoriasis.

Update on Ingenol mebutate gel (0.015%, 0.05%) Picato™, Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), and Hydrogel for skin and wound care (Vashe® Skin and Wound Hydrogel)

Learn about the role of biofilms in skin disorders like acne, atopic dermatitis, and chronic wounds. This article explores how biofilms contribute to disease pathogenesis, their resistance to antibiotics, and the latest conventional and innovative treatments aimed at targeting biofilm-associated skin conditions.

Imiquimod is the first of a new class of drugs to emerge in the treatment of various dermatologic disorders. As an immune response modifier, it has been shown to have potent antiviral and antitumor properties through the stimulation of innate and cell mediated immune pathways.

Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.

Cyanoacrylates are surgical adhesives that provide another option for wound closure. There are a number of surgical adhesives either currently available or under development. The presently available butylcyanoacrylates and octylcyanoacrylates are reviewed.

Pruritus, or itch, is a common sensation that causes a person to want to scratch. It is a complex process that may negatively impact quality of life. This overview provides information regarding the various management and treatment options for pruritus.

Update on Selumetinib capsules (Koselugo®), Crisaborole 2% ointment (Eucrisa®), Infliximab biosimilar for IV injection (Avsola™) and Baricitinib tablets (Olumiant®)

Update on drugs, approval dates, and comments for Nivolumab + ipilimumab (Opdivo® + Yervoy®), Etanercept for SC injection (Enbre®), Crisaborole 2% ointment (Eucrisa™ ), Hyaluronic acid dermal fillers Restylane® (Refyne Restylane® Defyne).

Moderate-to-severe psoriasis is known to affect millions of people around the globe. This chronic disease substantially impacts patients by impairing their quality of life. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.

Plasma skin regeneration technology uses energy delivered from plasma rather than light or radiofrequency. Plasma skin regeneration technology can be used at varying energies for different depths of effect, from superficial epidermal sloughing to deeper dermal heating.

A vast spectrum of topical anti-acne agents has emerged in response to new insights that have been gained through the understanding of disease pathophysiology and the need for clinicians to adopt an individualized therapeutic approach.

An overview and update of skin conditions and treatments introduced in 2001: Quick overview of drug name, indications and regulatory status

The success of botulinum toxin type A (BOTOX®, Allergan Inc.) in the cosmetic arena has acted as a stimulus for the development of other neurotoxins. Herein, we present an overview of botulinum toxin products for cosmetic applications that have received regulatory approval or are under development.

Treatment of metastatic melanoma using traditional chemotherapy regimens has been disappointing. However, recent work with agents that modify the host’s immune system (e.g., interleukins) have provided limited but encouraging results. Interleukins are a group of molecules involved in immune cell signaling.

Oral contraceptives (OCs) can reduce acne by lowering the production of adrenal and ovarian androgens, by inhibiting 5- alpha-reductase, which in turn, reduces the levels of dihydrotestosterone, and by stimulating sex hormone binding globulin (SHBG), thus reducing the levels of free testosterone.

An overview and update of skin treatments introduced in 2012: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US) and more drugs are covered.

Lasers and intense pulsed light sources are frequently used for the treatment of pigmented lesions, and the appropriate selection of devices for different lesions is vital to achieving satisfactory clinical outcomes. In the removal of melanocytic nevi, a combined approach with a long-pulse pigmented laser and a Q-switched laser is particularly applicable.

Update on: Tissue Engineered Collagen Matrix Oasis Wound Dressing Bexarotene Targretin Gel 1% Eflornithine Hydrochloride Vaniqa Cream 15% Biologically Active Dressing Composite Cultured Skin (CCS) Famciclovir Famvir Moxifloxacin Avelox/Avalox Finasteride 1mg Tablets Propecia

Fractional laser treatment with the 1,550nm erbium fiber laser (Fraxel® Laser, Reliant Technologies) has bridged the gap between the ablative and nonablative laser modalities used to treat the epidermal and dermal signs of skin aging.

Use of azelaic acid was associated with a significant reduction in inflammatory lesions, which persisted beyond the active treatment phase. Overall, azelaic acid 15% gel is an appropriate initial topical therapy for the treatment of moderate facial rosacea.

This guide will help you navigate the benefits of recent advancements in topical drug formulations and delivery systems. These innovations address limitations seen in older formulations, ensuring efficient and uniform delivery of active ingredients to target areas, improving patient acceptability, and enhancing treatment outcomes.

Although PDT remains an investigational treatment modality in dermatology, several important areas of development may ultimately lead to official and practical acceptance of PDT for the skin. Various uses of PDT are evaluated.

Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as “hypoallergenic“, “sensitive skin“, and ...

In this article, we examine the other approaches to PHN management. Claims have been made for products ranging from vitamins to snake venom for patients who develop PHN.

Update on Brimonidine tartrate 0.33% topical gel (Mirvaso®), Mechlorethamine gel (Valchlor™), OnabotulinumtoxinA for injection (Botox® Cosmetic), Ustekinumab (Stelara®), Certolizumab pegol (Cimzia®), Infliximab (Inflectra™), Efinaconazole 10% topical solution (Jublia®)

Tobacco smoking is a serious and preventable health hazard that can cause or exacerbate a number of diseases and shorten life expectancy. This article delves into the role of smoking as an etiologic factor in the development of skin disease.

An index for drug names and conditions including Accutane®, Aczone®, Adalimumab, Agalsidase Alfa, Aldara®, Alefacept, Alesion® Dry Syrup 1%, AlloDerm®, AMEVIVE® and other drugs.

Finasteride 1 mg (Propecia®, Merck) was approved by the US FDA December, 1997 for the treatment of male pattern hair loss (androgenetic alopecia, AGA) in men only. Safety and efficacy were demonstrated in men between 18 and 41 years of age with mild to moderate hair loss of the vertex and anterior mid-scalp area.

Optimal acne therapy must take into account not only acne type and severity, but also the impact of this skin disorder on the patient’s quality of life.

Update on Nanocrystalline Silver Cream NPI32101, Daptomycin for Injection CUBICIN®, Oral Alitretinoin BAL4079, Smallpox Vaccine ACAM2000, and news about new US FDA regulations.

There is no ideal filler, nor will there be a single product that can satisfy all requirements. However, RESTYLANE®, a non-animal, stabilized hyaluronic acid (NASHA, Medicis), is a very versatile augmenting agent. It has been in clinical use for 8 years and experience has shown it to be close to the ideal filler in many respects.

In February of this year, the US FDA issued a public health advisory to inform healthcare providers and patients about a potential cancer risk from the topical use of pimecrolimus (Elidel©, Novartis), approved by the FDA in December 2001, and tacrolimus (Protopic©, Astellas, formerly Fujisawa), approved in December 2000.

The botulinum neurotoxins (BTX) are an exciting group of therapeutic agents with dramatically expanding clinical indications. The US FDA has approved BOTOX® (BTX-A, Allergan) and Myobloc™ (BTX-B, Elan Pharmaceuticals) for the treatment of cervical dystonia.